These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 36705224)

  • 1. Role of Tocilizumab in the Treatment of COVID-19 Patients with Cytokine Storm: A Case Series.
    Basnet A; Shrestha MR; Thapa R; Tamang B; Shrestha A; Rawal P; Duwal Shrestha SK; Karki L; Rai SK
    JNMA J Nepal Med Assoc; 2022 Aug; 60(252):727-731. PubMed ID: 36705224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic Role of Tocilizumab in SARS-CoV-2-Induced Cytokine Storm: Rationale and Current Evidence.
    Pelaia C; Calabrese C; Garofalo E; Bruni A; Vatrella A; Pelaia G
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33802761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tocilizumab for the Treatment of COVID-19-Induced Cytokine Storm and Acute Respiratory Distress Syndrome: A Case Series From a Rural Level 1 Trauma Center in Western Pennsylvania.
    Suresh K; Figart M; Formeck S; Mehmood T; Abdel Salam M; Bassilly D
    J Investig Med High Impact Case Rep; 2021; 9():23247096211019557. PubMed ID: 34105382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.
    Kulanthaivel S; Kaliberdenko VB; Balasundaram K; Shterenshis MV; Scarpellini E; Abenavoli L
    Rev Recent Clin Trials; 2021; 16(2):138-145. PubMed ID: 32940187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunopathogenesis and treatment of cytokine storm in COVID-19.
    Kim JS; Lee JY; Yang JW; Lee KH; Effenberger M; Szpirt W; Kronbichler A; Shin JI
    Theranostics; 2021; 11(1):316-329. PubMed ID: 33391477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tocilizumab: A Therapeutic Option for the Treatment of Cytokine Storm Syndrome in COVID-19.
    Saha A; Sharma AR; Bhattacharya M; Sharma G; Lee SS; Chakraborty C
    Arch Med Res; 2020 Aug; 51(6):595-597. PubMed ID: 32482373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of Tocilizumab in Cytokine Storm and Improving Outcomes in COVID-19.
    Ali A; Kamjani MH; Kesselman MM
    Recent Pat Antiinfect Drug Discov; 2020; 15(2):104-112. PubMed ID: 32962623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Importance of the Timing of Tocilizumab Administration in Moderate to Severely Ill COVID-19: Single Centered Experience Case series.
    Tenda ED; Andrian S; Albert S; Asaf MM; Pitoyo CW; Setiati S; Subekti I
    Acta Med Indones; 2021 Jul; 53(3):319-325. PubMed ID: 34611072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive Cytokine Profiling of Patients with COVID-19 Receiving Tocilizumab Therapy.
    Lebedeva A; Molodtsov I; Anisimova A; Berestovskaya A; Dukhin O; Elizarova A; Fitzgerald W; Fomina D; Glebova K; Ivanova O; Kalinskaya A; Lebedeva A; Lysenko M; Maryukhnich E; Misyurina E; Protsenko D; Rosin A; Sapozhnikova O; Sokorev D; Shpektor A; Vorobyeva D; Vasilieva E; Margolis L
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How could perfluorocarbon affect cytokine storm and angiogenesis in coronavirus disease 2019 (COVID-19): role of hypoxia-inducible factor 1α.
    Moasefi N; Fouladi M; Norooznezhad AH; Yarani R; Rahmani A; Mansouri K
    Inflamm Res; 2021 Jul; 70(7):749-752. PubMed ID: 34173853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of cytokine storm on severity of COVID-19 disease in a private hospital in West Jakarta prior to vaccination.
    Ramatillah DL; Gan SH; Pratiwy I; Syed Sulaiman SA; Jaber AAS; Jusnita N; Lukas S; Abu Bakar U
    PLoS One; 2022; 17(1):e0262438. PubMed ID: 35077495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab.
    Morrison AR; Johnson JM; Griebe KM; Jones MC; Stine JJ; Hencken LN; To L; Bianchini ML; Vahia AT; Swiderek J; Ramesh MS; Peters MA; Smith ZR
    J Autoimmun; 2020 Nov; 114():102512. PubMed ID: 32646770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heme oxygenase-1 (HO-1) cytoprotective pathway: A potential treatment strategy against coronavirus disease 2019 (COVID-19)-induced cytokine storm syndrome.
    Rossi M; Piagnerelli M; Van Meerhaeghe A; Zouaoui Boudjeltia K
    Med Hypotheses; 2020 Nov; 144():110242. PubMed ID: 33254548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes in COVID-19 patients treated with tocilizumab: An individual patient data systematic review.
    Antwi-Amoabeng D; Kanji Z; Ford B; Beutler BD; Riddle MS; Siddiqui F
    J Med Virol; 2020 Nov; 92(11):2516-2522. PubMed ID: 32436994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of β-Blockers on the Sympathetic and Cytokines Storms in Covid-19.
    Al-Kuraishy HM; Al-Gareeb AI; Mostafa-Hedeab G; Kasozi KI; Zirintunda G; Aslam A; Allahyani M; Welburn SC; Batiha GE
    Front Immunol; 2021; 12():749291. PubMed ID: 34867978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tocilizumab as a Treatment for 'Cytokine Storm Syndrome' in COVID-19: A Case Report.
    Syam AF; Pitoyo CW; Suhendro S; Zulkarnain B; Indrasari ND; Aditianingsih D; Irawan C; Susilo A; Rumende CM; Wijaya IP; Ibrahim F; Rasmin M; Alwi I; Makmun D
    Acta Med Indones; 2021 Apr; 53(2):194-201. PubMed ID: 34251348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble interleukin-6 receptor in the COVID-19 cytokine storm syndrome.
    Chen LYC; Biggs CM; Jamal S; Stukas S; Wellington CL; Sekhon MS
    Cell Rep Med; 2021 May; 2(5):100269. PubMed ID: 33899032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coronavirus Disease-2019 Treatment Strategies Targeting Interleukin-6 Signaling and Herbal Medicine.
    Dzobo K; Chiririwa H; Dandara C; Dzobo W
    OMICS; 2021 Jan; 25(1):13-22. PubMed ID: 32857671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COVID-19: Consider IL-6 receptor antagonist for the therapy of cytokine storm syndrome in SARS-CoV-2 infected patients.
    Chakraborty C; Sharma AR; Bhattacharya M; Sharma G; Lee SS; Agoramoorthy G
    J Med Virol; 2020 Nov; 92(11):2260-2262. PubMed ID: 32462717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can emapalumab be life saving for refractory, recurrent, and progressive cytokine storm caused by COVID-19, which is resistant to anakinra, tocilizumab, and Janus kinase inhibitors.
    Cure E; Kucuk A; Cure MC
    Indian J Pharmacol; 2021; 53(3):226-228. PubMed ID: 34169908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.